Sean J. Hart, PHD
Chief Executive Officer & Chief Scientific Officer
Dr. Hart is a highly accomplished leader, innovator and scientist who has developed transformative, cutting edge technologies throughout his career. In late 2012, Dr. Hart founded LumaCyte, a revolutionary biopharmaceutical research, instrumentation and analytics company.
LumaCyte offers pharmaceutical and biotechnology companies an advanced label-free approach to single cell analysis and sorting, providing researchers a powerful new tool for biomanufacturing and clinical development, viral infectivity for vaccine manufacturing, cancer biology R&D, infectious disease, and pre-clinical drug discovery. Dr. Hart and his team developed LumaCyte’s Laser Force Cytology (LFC) technology which offers significant advancement over traditional cell based methods, providing biopharmaceutical companies a rapid, automated cell based assay that delivers significant improvements in speed, accuracy and sensitivity.
Dr. Hart has published over 50 peer reviewed journal articles, numerous invited and contributed presentations, 4 patents issued / 4 pending, and has managed large research teams with multi-million dollar budgets. Dr. Hart has extensive experience in a diverse range of research areas including spectroscopy, laser trapping and separation, optical engineering, chromatography, chemical and biochemical separation, statistical data analysis/calibration and artificial intelligence. Dr. Hart received his PhD in Chemistry from Tufts University in 1998.
Renée A. Hart
President & Chief Business Officer
Renee leads LumaCyte’s corporate development, investor relations, sales and marketing, and is currently Managing Member of the Board of Directors. She has over 20 years of business development and strategic alliance experience across the biopharmaceutical and clinical development service arenas. Renee’s collaborative spirit and strong focus on problem solving and solution management has garnered her many long-term trusted relationships, managing large scale, highly complex, multi-million dollar partnership level transactions.
Renee brings significant corporate and executive level leadership experience to her role and has sat on multiple executive governance committees across her tenure. Renee has a bachelors of science degree in biology from Marshall University.
Colin Hebert, PHD
Vice President, Biotechnology
Dr. Hebert earned a Ph.D. in Bioengineering from the Fischell Department of Bioengineering at the University of Maryland. He was part of the technical team at the Naval Research Laboratory that developed the technology underlying LumaCyte's Radiance instrument. In addition to his contributions to the label-free cell analysis platform, he has also authored 10 peer reviewed journal articles
In his role at LumaCyte, Dr. Hebert oversees technical operations including instrument R&D, LumaCyte’s BSL-2 cell culture facilities, designing internal and external biological experiments and managing the design and construction of our analytical platforms.